证券代码：301201 证券简称：诚达药业 公告编号：2023-037 诚达药业股份有限公司 第五届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 表决结果：7 票同意，0 票反对，0 票弃权。 （二）审议通过《关于<2023 年半年度募集资金存放与使用情况专项报告> 的议案》 具体内容详见公司同日披露于巨潮资讯网（http://www.cninfo.com.cn）的 《2023 年半年度募集资金存放与使用情况专项报告》。 诚达药业股份有限公司（以下简称"公司"）第五届董事会第三次会议于 2023 年 8 月 21 日在公司会议室以现场结合通讯的方式召开。会议通知已于 2023 年 8 月 11 日通过电话、邮件的方式送达全体董事。本次会议应出席董事 7 人，实际 出席董事 7 人，其中董事俞毅、崔孙良以通讯方式出席会议，公司监事、高级管 理人员列席会议。会议由董事长葛建利女士召集和主持。本次会议的召集和召开 符合有关法律、行政法规、部门规章和《公司章程》的规定，形成的决议合法有 效。 二、董事会会议审议情况 ...

证券代码：301201 证券简称：诚达药业 公告编号：2023-038 诚达药业股份有限公司 第五届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 诚达药业股份有限公司（以下简称"公司"）第五届监事会第三次会议于 2023 年 8 月 21 日在公司会议室以现场方式召开。会议通知已于 2023 年 8 月 11 日通 过电话、邮件的方式送达各位监事。本次会议应出席监事 3 人，实际出席监事 3 人。会议由监事会主席陈维汉先生主持，董事会秘书列席会议。 会议召开、召集符合有关法律、行政法规、部门规章和《公司章程》的规定， 形成的决议合法有效。 二、监事会会议审议情况 （一）审议通过《关于<2023 年半年度报告>及其摘要的议案》 经审核，监事会认为：公司董事会编制和审核的 2023 年半年度报告全文及 摘要的程序符合法律、行政法规、中国证监会和深圳证券交易所的规定，报告内 容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈 述或者重大遗漏。 具体内容详见公司同日披露于巨潮资讯网（http:// ...

证券代码：301201 证券简称：诚达药业 公告编号：2023-042 诚达药业股份有限公司 关于召开2023年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 （一）股东大会届次：2023年第二次临时股东大会 （二）股东大会的召集人：公司董事会 公司于2023年8月21日召开的第五届董事会第三次会议审议通过了《关于召开2023 年第二次临时股东大会的议案》，决议召开本次股东大会。 （三）会议召开的合法、合规性：本次股东大会的召开符合有关法律、行政法规、 部门规章、规范性文件、深圳证券交易所业务规则和公司章程等的规定。 （四）会议召开的日期、时间： 1、现场会议时间：2023年9月7日（星期四）下午14：00 2、网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为2023 年9月7日的交易时间，即9:15-9:25、9:30—11:30和13:00—15:00；通过深圳证券交 易所互联网投票的具体时间为：2023年9月7日9:15—15:00。 （五）会议的召开方式：本次股东大会采用现场表决与网络投 ...

大的市场风险。投资者应充分了解创业板的投资风险及本公司所披露的风险因素，审慎作出投 资决定。 金凯（辽宁）生命科技股份有限公司 （辽宁省阜新市阜蒙县伊吗图镇氟化工园区安仁路 6 号） 招股说明书 （住所：北京市朝阳区安立路 66 号 4 号楼） 首次公开发行股票并在创业板上市 保荐人（主承销商） 创业板风险提示：本次发行股票拟在创业板上市，创业板公司具有创新投入大、新旧产业融合 存在不确定性、尚处于成长期、经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 金凯（辽宁）生命科技股份有限公司 招股说明书 声明与承诺 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 | 发行股票类型 | 股） 人民币普通股（ ...

证券代码：301201 证券简称：诚达药业 诚达药业股份有限公司 投资者关系活动记录表 编号：2023-003 | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | | 线上参与公司2022年度业绩说明会的全体投资者 | | 参与单位名称及人员姓名 | | | 时间 | 2023年05月12日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | | 董事长 葛建利女士 董事、总经理 卢刚先生 | | | 独立董事 汪萍女士 | | 上市公司接待人员姓名 | 副总经理、董事会秘书 杨晓静女士 | | | 财务总监 费超先生 | | | 保荐代表人 杨科先生 | | | 1.高溢价减持，接盘的是谁？当中有没有利益输送？2.公司有 | | | 没有欺诈发行，股价5月5日比发行价亏损达40%以上？3.公司有没有 | | 投资者关系活动主要内容 | 预期稳定股价的措施 ...

重要内容提示： 证券代码：301201 证券简称：诚达药业 公告编号：2023-025 诚达药业股份有限公司 关于举办2022年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 二、参加人员 董事长 葛建利女士，董事、总经理 卢刚先生，独立董事 汪萍女士，副总 经理、董事会秘书 杨晓静女士，财务总监 费超先生，保荐代表人 杨科先生（如 遇特殊情况，参会人员可能进行调整）。 三、投资者参加方式 诚达药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 24 日在巨潮 资讯网（www.cninfo.com.cn）上披露了《2022 年年度报告》及《2022 年年度报 告摘要》。为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情 况，公司定于 2023 年 5 月 12 日（星期五）15:00-17:00 在"价值在线"（www.ir- online.cn）举办公司 2022 年度业绩说明会，与投资者进行沟通和交流，广泛听取 投资者的意见和建 ...

金凯（辽宁）生命科技股份有限公司 （辽宁省阜新市阜蒙县伊吗图镇氟化工园区安仁路 6 号） 首次公开发行股票并在创业板上市 招股说明书 （注册稿） 免责声明：本公司的发行申请尚需经深圳证券交易所和中国证监会履行相应程序。 本招股说明书不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当以 正式公告的招股说明书全文作为投资决定的依据。 保荐机构（主承销商） （住所：北京市朝阳区安立路 66 号 4 号楼） 金凯（辽宁）生命科技股份有限公司 招股说明书 声明与承诺 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 发行股票类型 人民币普通股（A 股） 发行股数 本次公开发行新股不超过 2,150. ...

科创板风险提示：本次发行股票拟在科创板上市，科创板公司具有研发 投入大、经营风险高、业绩不稳定、退市风险高等特点,投资者面临较大的市 场风险。投资者应充分了解科创板的投资风险及本公司所披露的风险因素， 审慎作出投资决定。 cao 上海康鹏科技股份有限公司 Shanghai Chemspec Corporation 上海市普陀区祁连山南路 2891 弄 200 号 1 幢 首次公开发行股票并在科创板上市 招股说明书 （注册稿） 声明:公司的发行申请尚需经上海证券交易所和中国证监会履行相应程 序。本招股说明书不具有据以发行股票的法律效力，仅供预先披露之用。投 资者应当以正式公告的招股说明书作为投资决定的依据。 保荐人（主承销商） （北京市朝阳区安立路 66 号 4 号楼） 上海康鹏科技股份有限公司 招股说明书（注册稿） 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对注 册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对 发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的 ...

Financial Performance - The company's revenue for Q3 2022 was ¥88,418,646.40, a decrease of 6.64% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 was ¥26,956,187.26, an increase of 37.74% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥15,226,607.83, down 24.29% from the previous year[5] - The basic earnings per share for Q3 2022 was ¥0.2788, reflecting a 3.31% increase year-on-year[5] - The net profit for the third quarter of 2022 was CNY 91,990,029.78, an increase of 30.9% compared to CNY 70,372,208.94 in the same period last year[21] - Operating profit reached CNY 109,884,155.18, up from CNY 82,963,144.01, reflecting a growth of 32.3% year-over-year[21] - The total comprehensive income attributable to the parent company was CNY 92,047,145.90, compared to CNY 70,504,796.15 in the previous year, marking a growth of 30.5%[21] Assets and Equity - Total assets at the end of Q3 2022 reached ¥2,289,275,234.90, representing a 235.07% increase compared to the end of the previous year[5] - As of September 30, 2022, the total assets of Chengda Pharmaceutical Co., Ltd. amounted to CNY 2,289,275,234.90, a significant increase from CNY 683,227,154.78 at the beginning of the year[17] - The total equity attributable to shareholders increased to CNY 2,199,783,842.96 from CNY 529,243,641.45, indicating a significant growth in shareholder value[19] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥12,955,580.95, a significant decrease of 85.17%[9] - Cash flow from operating activities generated CNY 12,955,580.95, a significant decrease of 85.2% compared to CNY 87,375,186.65 in the previous year[22] - The company experienced a decrease in cash flow from operating activities due to increased cash payments for goods and services, totaling CNY 198,426,196.31, up from CNY 107,465,682.07[22] - The company reported a net cash outflow from investing activities of CNY -1,102,244,307.66, compared to CNY -116,301,731.56 in the same period last year[23] - The company raised CNY 1,640,224,998.21 from financing activities, a substantial increase compared to CNY 46,401,624.00 in the previous year[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,385[11] - The largest shareholder, Ge Jianli, holds 27.17% of shares, totaling 26,269,600 shares[11] - Shenzhen Shengtai Investment Management Co., Ltd. holds 16.03% of shares, totaling 15,500,000 shares[11] - Huang Honglin, another major shareholder, owns 12.62% of shares, amounting to 12,205,000 shares[11] - The total number of restricted shares at the end of the period is 73,318,970[14] - The company has no new restricted shares added during the reporting period[14] - The total number of shares held by the top ten unrestricted shareholders is 1,645,000[14] - The company plans to lift restrictions on certain shares by January 2023[14] - The total number of shares held by WANG ZHE and Shenzhen Jiuheng Investment Advisory Co., Ltd. is 2,000,000 each[14] - The company has a strategic placement plan for employee participation with 796,865 shares[14] Operational Highlights - The company reported a significant increase in prepayments, which rose by 322.58% to ¥21,903,046.51 due to increased raw material payments[8] - Chengda Pharmaceutical established a new subsidiary, Shanghai Ruijiyuan Biotechnology Co., Ltd., with a total investment of CNY 20 million, enhancing its operational capabilities in biotechnology[15] - The company's inventory as of September 30, 2022, was CNY 173,794,253.43, up from CNY 104,183,626.72 at the beginning of the year, reflecting a growth of approximately 66.8%[17] - Research and development expenses for the third quarter of 2022 were CNY 14,626,261.48, compared to CNY 11,720,223.57 in the previous year, marking an increase of approximately 25.8%[20] Financial Performance Comparison - The company's total revenue for the third quarter of 2022 was CNY 305,647,514.60, representing an increase of 5.5% compared to CNY 289,859,993.58 in the same period last year[20] - The total operating costs for the third quarter of 2022 were CNY 231,232,772.85, up from CNY 211,715,175.40 year-over-year, indicating a rise of approximately 9.2%[20] - The company reported a financial income of CNY 1,024,724.41 for the third quarter of 2022, compared to CNY 229,934.80 in the same period last year, indicating a strong improvement in financial performance[20]

Financial Performance - ChengDa Pharmaceuticals reported a revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[17]. - The company achieved a net profit of RMB 80 million, up 20% compared to the same period last year[17]. - The company's operating revenue for the reporting period was ¥217,228,868.20, representing an increase of 11.31% compared to the same period last year[25]. - Net profit attributable to shareholders was ¥65,090,958.64, reflecting a growth of 27.79% year-over-year[25]. - The company achieved a revenue of CNY 217.23 million, representing a year-on-year growth of 11.31%[36]. - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was CNY 47.72 million, with a slight increase of 0.07% year-on-year[36]. - The company reported a total of 110,816.71 million RMB in raised funds, with plans to invest 20,000 million RMB in expanding the production of pharmaceutical intermediates and food additives[71]. - The total revenue for the first half of 2022 was 1.5 billion, representing a 24% increase compared to the previous year[182]. - The net profit attributable to shareholders was 513 million, with a profit margin of 3.0%[183]. - The company reported a total equity of 72.5 billion, reflecting a 5.0% increase year-over-year[181]. Research and Development - The company is investing RMB 50 million in R&D for new technologies aimed at enhancing drug efficacy and safety[17]. - The company has been providing CDMO services for new drug key intermediates during preclinical and clinical stages, enhancing drug development efficiency for clients[33]. - The company is actively involved in the R&D of new projects, such as NP2103 for treating uterine fibroids, which is expected to support its innovative development[39]. - The company is focusing on the development of new drug intermediates, which is expected to enhance its competitive edge in the market[34]. - The company has completed small-scale research and process development for multiple drug intermediates, including NP2105, NP2109, NP2113, and NP2115, focusing on optimizing processes and ensuring safety[40]. - The company is advancing its research in the oncology field with projects like NP2202 and NP2216, targeting specific cancer treatments and enhancing its market competitiveness[41]. - The company is committed to quality research, adhering to ICH standards, and exploring proprietary process routes for its drug development projects[41]. - The company has formed a leading R&D team and is increasing investment in R&D to enhance its capabilities and establish an independent intellectual property system[44]. - Research and development expenses increased to CNY 9,550,030.45, up from CNY 7,663,750.46, marking a rise of 24.6%[169]. - The company has initiated a strategic acquisition of a smaller competitor, expected to close by Q4 2022, which will enhance its product offerings[182]. Market Expansion and Strategy - ChengDa Pharmaceuticals plans to launch two new products in Q4 2022, targeting a market expansion of 30% in the next fiscal year[17]. - The company has implemented a new marketing strategy focusing on digital channels, aiming for a 40% increase in online sales[17]. - Future guidance estimates a revenue growth of 10-15% for the full year 2022, driven by new product launches and market expansion[17]. - The company plans to expand its market presence by entering three new regions by the end of 2022[182]. - The company plans to expand its market presence through new product launches and strategic partnerships in the upcoming quarters[186]. - The company is exploring potential mergers and acquisitions to enhance its market share and operational capabilities[186]. Financial Position and Investments - Total assets increased by 230.24% to ¥2,256,287,976.58 at the end of the reporting period[25]. - The net assets attributable to shareholders rose by 310.53% to ¥2,172,703,475.70 compared to the end of the previous year[25]. - The company’s cash and cash equivalents increased significantly by 2,973.55% to ¥484,916,951.65, primarily due to the absorption of investment during the reporting period[52]. - The company’s investment activities generated a cash outflow of ¥1,063,984,401.45, a 1,720.58% increase compared to the previous year, due to increased fixed asset investments[52]. - The company has established a special account for raised funds, ensuring compliance with regulatory requirements[67]. - The company has completed 100% of the investment for the supplementary working capital project, totaling RMB 11,000 million[70]. Environmental and Safety Management - The company emphasizes safety production management and environmental protection, implementing strict safety protocols and pollution control measures to mitigate risks[83]. - The company has established a robust EHS management system, achieving ISO14001 and ISO45001 certifications, ensuring safety production and ecological environment protection[48]. - The company has installed online monitoring devices at its wastewater and RTO discharge outlets, ensuring compliance with environmental regulations[95]. - The company reported a wastewater treatment capacity of 95,746.98 tons, with a pollution treatment efficiency of 91.69% for COD removal[94]. - The company has a VOCs removal efficiency of 98% from its RTO facility, operating for 4,128 hours[94]. Shareholder and Corporate Governance - The company emphasizes the protection of shareholder and creditor rights, ensuring compliance with relevant laws and regulations, and maintaining a stable financial condition without any major related party fund occupation[101]. - Employee rights are prioritized, with timely payment of salaries and contributions to social insurance, alongside a comprehensive training system to enhance professional skills[102]. - The company has not experienced any significant changes in the expected benefits from the projects funded by raised capital[70]. - The company has not engaged in any non-operating fund occupation by major shareholders or related parties during the reporting period[108]. - The company has not issued any external guarantees that violate regulations during the reporting period[109]. Legal and Compliance - The company submitted a written rectification report to the regulatory authority following a warning letter received in March 2022, demonstrating proactive compliance measures[114]. - The company did not implement any stock incentive plans or employee shareholding plans during the reporting period[90]. - There were no significant lawsuits or arbitration matters during the reporting period, indicating a stable legal environment for the company[112].